Riverside, California – Huntington’s disease causes involuntary movements and dementia, has no cure, and is fatal. For the first time, UC Riverside scientists have shown they can slow its progression in flies and worms, opening the door to human treatments. Key to understanding these advancements is the way that genetic...
Latest News
Riverside, Calif. – Meet MYC, the shapeless protein responsible for making the majority of human cancer cases worse. UC Riverside researchers have found a way to rein it in, offering hope for a new era of treatments. In healthy cells, MYC helps guide the process of transcription, in which genetic...
New York, NY – A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer treatments, according to a new study from researchers at Weill Cornell Medicine. In the study, published Dec. 26 in Cell Stem Cell, the scientists...
TEL AVIV, Israel — SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center...
TEL AVIV, Israel — SciSparc Ltd. (Nasdaq: SPRC) a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announces the initiation of patient recruitment for its clinical trial in children suffering from autism spectrum disorder (“ASD”) at Soroka Medical Center...
GROSSE POINTE, Mich. — SciTech Development, a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has dosed the first patient in its Phase 1 clinical trial with lead cancer drug candidate, ST-001 nanoFenretinide. “There have been relatively few new cancer breakthroughs for...
HANGZHOU, China and SAN FRANCISCO, CA — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive topline results from a Phase 3 clinical trial of ecnoglutide (XW003) in Chinese adults with type 2 diabetes mellitus (T2DM). Ecnoglutide...
Granada, Spain – A study carried out by the MP20-Biomarkers of Metabolic and Bone Diseases research group at the Biohealth Research Institute in Granada (ibs.GRANADA), led by UGR Professor Manuel Muñoz Torres, has provided significant insights into the role of sclerostin in protecting against atherosclerosis in patients with type 2...
ARLINGTON, Texas – Scott Schliebner, MPH, a leading clinical strategist for drug development of rare diseases, is joining 2M Clinical Inc. on Dec. 1. Schliebner, who most recently was Senior Vice president for Scientific Affairs and Therapeutic Expertise at PRA Health Sciences, has a 25-year successful track record of providing...
JUPITER, FL. – Current tests to identify specific strains of infectious prions, which cause a range of transmissible diseases (such as mad cow) in animals and humans, can take anywhere from six months to a year to yield results – a time-lag that may put human populations at risk. Now,...